Physician profile
Mark Daniel Romer
NPI 1023058427
$12,202.86
in general payments reported to CMS, 2019-2025
84 companies · $2,754 in 2025
The $2,754 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,379 · 2020: $347 · 2021: $478 · 2022: $1,440 · 2023: $2,699 · 2024: $3,105 · 2025: $2,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,509 · Education: $49.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,508.82 |
| Education | $49.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,215.93 | 2019-2025 | Kisqali, Piqray |
| Pfizer INC. | $837.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $798.38 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $653.44 | 2022-2025 | Enhertu, Imfinzi, Calquence |
| Janssen Biotech, INC. | $587.00 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Daiichi Sankyo INC. | $480.19 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $430.51 | 2021-2025 | Reblozyl, Opdivo, Pomalyst |
| Abbvie INC. | $414.32 | 2023-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $398.88 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $387.80 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $353.11 | 2019-2025 | |
| Incyte Corporation | $309.47 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $283.81 | 2019-2025 | |
| Genentech USA, INC. | $276.86 | 2019-2025 | Polivy, Lunsumio, Tecentriq |
| Bayer Healthcare Pharmaceuticals INC. | $272.00 | 2019-2025 |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $268.64 | 2019-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $199.74 | 2019-2025 | Libtayo, Lynozyfic |
| E.R. Squibb & Sons, L.L.C. | $182.26 | 2020-2025 | Opdivo, Krazati |
| Jazz Pharmaceuticals INC. | $171.35 | 2019-2025 | |
| Tersera Therapeutics LLC | $169.44 | 2019-2025 | Zoladex, Quzyttir |
| Array Biopharma INC | $147.32 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Takeda Pharmaceuticals U.S.A., INC. | $142.26 | 2020-2024 | Iclusig, Fruzaqla, Alunbrig |
| Taiho Oncology, INC. | $142.07 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.49 | 2019-2024 | Gilotrif |
| Stemline Therapeutics INC. | $134.86 | 2023-2025 | Orserdu, Elzonris |
| Glaxosmithkline, LLC. | $124.94 | 2023-2025 | Ojjaara, Blenrep, Shingrix |
| Astellas Pharma US INC | $122.56 | 2020-2025 | Padcev, Xtandi, Xospata |
| Kite Pharma, INC. | $106.16 | 2021-2025 | Yescarta |
| Myriad Genetic Laboratories, INC. | $103.16 | 2023-2024 | Myrisk |
| Sobi, INC | $100.30 | 2023-2025 | |
| Octapharma USA, INC. | $96.48 | 2023-2025 | Octagam Immune Globulin (Human) |
| Alexion Pharmaceuticals, INC. | $85.02 | 2024-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $83.74 | 2021-2025 | Onivyde, Tazverik |
| Tempus Ai, INC | $81.42 | 2024-2025 | Xt Cdx |
| Sun Pharmaceutical Industries INC. | $81.30 | 2022-2024 | Yonsa, Odomzo |
| Foundation Medicine, INC. | $76.93 | 2019-2023 | |
| Beone Medicines USA, INC. | $72.55 | 2025 | Brukinsa, Tevimbra |
| Amgen INC. | $65.52 | 2019-2023 | Lumakras, Kyprolis |
| Mirati Therapeutics, INC. | $61.82 | 2023-2024 | Krazati |
| Cti Biopharma Corp. | $61.60 | 2022-2023 | Vonjo |
| Genmab U.S., INC. | $61.24 | 2023-2025 | Tivdak |
| Beigene USA, INC. | $59.78 | 2022-2023 | Brukinsa |
| Accord Healthcare, INC. | $58.77 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $58.57 | 2022-2024 | Clonoseq |
| Clovis Oncology, INC. | $57.24 | 2019 | |
| Zimmer Biomet Holdings, INC. | $54.58 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Cumberland Pharmaceuticals, INC. | $53.68 | 2024-2025 | Sancuso |
| Pharmacosmos Therapeutics INC. | $53.00 | 2024-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $52.80 | 2019-2024 | Tavalisse, Rezlidhia |
| Deciphera Pharmaceuticals INC. | $52.80 | 2022-2025 | Qinlock, Romvimza |
| Springworks Therapeutics, INC. | $51.71 | 2024-2025 | Ogsiveo |
| Helsinn Therapeutics (U.S.), INC. | $46.66 | 2019-2024 | Valchlor |
| Puma Biotechnology, INC. | $46.10 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $43.37 | 2022-2023 | |
| Exelixis INC. | $43.19 | 2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $42.20 | 2025 | |
| Emd Serono, INC. | $41.53 | 2023-2025 | Tepmetko |
| Sumitomo Pharma America, INC. | $38.92 | 2023-2024 | Orgovyx |
| Caris Mpi, INC. | $37.40 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $35.61 | 2024-2025 | Ayvakit |
| Mylan Institutional INC. | $33.47 | 2019-2023 | Ogivri, Fulphila |
| Eusa Pharma (US) LLC | $32.99 | 2019 | |
| Adc Therapeutics America, INC. | $32.16 | 2022-2024 | |
| Aurobindo Pharma USA, INC. | $31.95 | 2019 | |
| Kyowa Kirin, INC. | $31.20 | 2023-2024 | Poteligeo |
| Seagen INC. | $25.85 | 2022 | |
| Janssen Scientific Affairs, LLC | $24.15 | 2019 | |
| Spectrum Pharmaceuticals INC. | $22.14 | 2025 | Rolvedon |
| Apellis Pharmaceuticals, INC. | $20.00 | 2023 | Empaveli |
| Sandoz INC. | $19.06 | 2024 | Cyclophosphamide |
| Pharmaessentia USA Corporation | $18.61 | 2023 | Besremi |
| Lexicon Pharmaceuticals, INC. | $18.48 | 2019 | |
| Karyopharm Therapeutics INC. | $18.26 | 2023 | Xpovio |
| Tolmar, INC. | $17.91 | 2023 | |
| Verastem, INC. | $17.47 | 2020 | |
| Legend Biotech USA INC. | $16.98 | 2024 | |
| Iovance Biotherapeutics, INC. | $16.80 | 2025 | Amtagvi |
| Sirtex Medical INC | $15.79 | 2024 | Sir-Spheres Microspheres |
| Azurity Pharmaceuticals, INC. | $15.53 | 2024 | Vivimusta |
| Syndax Pharmaceuticals, INC. | $15.29 | 2025 | |
| Alnylam Pharmaceuticals INC. | $14.64 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.78 | 2024 | Avastin |
| Janssen Pharmaceuticals, INC | $13.00 | 2019 | |
| Tesaro, INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
Keytruda $637Enhertu $435Imbruvica $389Jaypirca $344Verzenio $341Epkinly $329Welireg $268Kisqali $229Reblozyl $229Darzalex $227Opdivo $163Tecvayli $157Venclexta $148Elrexfio $148Jakafi $145Ibrance $137Imfinzi $136Pluvicto $135Retevmo $131Adcetris $131Inqovi $125Lonsurf $125Lynparza $120Fabhalta $118Braftovi $118Nubeqa $115Scemblix $114Lorbrena $113Bosulif $112Injectafer $105Myrisk $103Orgovyx $98.70Octagam Immune Globulin (Human) $96.48Erleada $96.35Xtandi $95.72Vonjo $95.60Gilotrif $95.13Lenvima $93.34Mektovi $92.04Trodelvy $88.28Xofigo $87.54Orserdu $87.24Monjuvi $86.62Ultomiris $85.02Zepzelca $82.17Polivy $77.52Brukinsa $77.51Vitrakvi $77.00Stivarga $77.00Krazati $75.54Libtayo $74.80Talvey $73.05Calquence $70.35Pemazyre $68.50Xt Cdx $67.98Xalkori $67.86Balversa $67.49Yescarta $67.48Tivdak $61.24Zoladex $61.02Pomalyst $60.60Lunsumio $58.67Oxbryta $56.68Tecentriq $54.71Gel-One Cross-Linked Hyaluronate $54.58Carvykti $53.88Sancuso $53.68Padcev $53.13Monoferric $53.00Ojjaara $52.17Ogsiveo $51.71Comirnaty $48.01Elzonris $47.62Talzenna $47.35Cabometyx $43.19Promacta $42.39Fotivda $42.20Iclusig $42.10Enjaymo $41.77Lutathera $41.53Akeega $39.53Tasigna $38.29Mi Cancer Seek $37.40Clonoseq $37.04Ayvakit $35.61Qinlock $35.21Lynozyfic $34.91Blenrep $34.48Hercessi $33.87Odomzo $33.22Yonsa $33.22Paxlovid $32.35Tecentriq Hybreza $31.26Poteligeo $31.20Itovebi $30.40Ziihera $30.00Rezlidhia $29.07Tavalisse $29.07Perjeta $27.58Tevimbra $27.14
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Romer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.